Pamela Devine, RN, clinical nurse specialist, Philadelphia Veterans Administration Medical Center, discusses some of the psychosocial issues that men face when they are receiving treatment for their prostate cancer.
Pamela Devine, RN, clinical nurse specialist, Philadelphia Veterans Administration Medical Center, discusses some of the psychosocial issues that men face when they are receiving treatment for their prostate cancer.
Devine says there is a huge component to the psychology of prostate cancer. In addition to sexual issues that men might face after treatment or surgery, men can also feel fatigue. Feeling fatigue may hinder these patients from going about their daily duties.
Sometimes, patients with cancer feel that they can no longer relate to other people because of their disease, Devine says. However, 95% of patients with early-stage prostate cancer go on to survive their disease.
Enfortumab Vedotin Plus Pembrolizumab Improves Outcomes vs Chemo in Urothelial Cancer
April 20th 2024Patients with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin plus pembrolizumab experienced a reduction in the risk for disease progression or death vs chemotherapy.
Maintenance Avelumab Has Similar Efficacy in Real World for Urothelial Cancer
March 5th 2024Patients with metastatic urothelial cancer treated with frontline maintenance therapy with avelumab following platinum-based chemotherapy in the real-world setting had similar outcomes as observed in the JAVELIN Bladder 100 trial.
Key Advances in Cancer Survivorship Toxicity Management
July 15th 2022In this episode of The Vitals, Lidia Schapira, MD, FASCO, recounts highlights from the 2022 ASCO Symptoms and Survivorship track and underscores key takeaways for practitioners seeking to enhance the delivery of cancer survivorship care.
Enfortumab Vedotin Plus Pembrolizumab Improves Outcomes vs Chemo in Urothelial Cancer
April 20th 2024Patients with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin plus pembrolizumab experienced a reduction in the risk for disease progression or death vs chemotherapy.
Maintenance Avelumab Has Similar Efficacy in Real World for Urothelial Cancer
March 5th 2024Patients with metastatic urothelial cancer treated with frontline maintenance therapy with avelumab following platinum-based chemotherapy in the real-world setting had similar outcomes as observed in the JAVELIN Bladder 100 trial.
Key Advances in Cancer Survivorship Toxicity Management
July 15th 2022In this episode of The Vitals, Lidia Schapira, MD, FASCO, recounts highlights from the 2022 ASCO Symptoms and Survivorship track and underscores key takeaways for practitioners seeking to enhance the delivery of cancer survivorship care.
Relapsed/Refractory Follicular Lymphoma May Respond to Loncastuximab Tesirine Plus Rituximab
Cilta-cel Demonstrates 99.4% ORR in Lenalidomide-Refractory Myeloma
Multidisciplinary Infrastructure Streamlines Cancer Care During Drug Shortages
Workflow, Educational Tools Improve Use of Silicone Film to Prevent Radiation Dermatitis
2 Commerce Drive
Cranbury, NJ 08512